Aging and heart failure: changing demographics and implications for therapy in the elderly
Aging and heart failure: changing demographics and implications for therapy in the elderly
复制标题
DOI：
10.1007/s10741-010-9164-8
复制
发表时间：
2010-09-01
影响因子：
4.6
通讯作者：
Jugdutt, Bodh I.
中科院分区：
文献类型：
--
作者：
Jugdutt, Bodh I.
老年人口（每千分之一日元65岁）正在增加，发病率、住院率、费用和心力衰竭造成的死亡率也在增加。心衰是一种累进性疾病，叠加在持续的衰老过程中。HF的两大类，HF合并左室收缩功能障碍或低射血分数（HF/low- ef）和HF合并保留射血分数（HF/PEF）在老年人中同样普遍。在主要非老年患者中治疗HF/低ef的试验显示老年患者死亡率降低。相比之下，HF/PEF的试验并未显示老年或非老年患者的死亡率降低。老年人心衰药物治疗具有挑战性，需要个体化治疗，并考虑一些与衰老相关的变化。为了提高老年心衰患者的发病率和死亡率，需要对衰老生物学进行更多的研究，并在老年患者中进行更多的临床试验。
The elderly population (age a parts per thousand yen65) is increasing and with it morbidity, hospitalizations, costs and mortality due to heart failure (HF). HF is a progressive disorder that is superimposed on an on-going aging process. The two broad categories of HF, HF with left ventricular (LV) systolic dysfunction or low ejection fraction (HF/low-EF) and HF with preserved ejection fraction (HF/PEF) are equally prevalent in the elderly. Trials of therapy for HF/low-EF in primarily non-elderly patients showed mortality benefit in elderly patients. In contrast, trials for HF/PEF have not shown mortality benefit in elderly or non-elderly patients. HF pharmacotherapy in the elderly is challenging and needs to be individualized and consider several aging-related changes. More research into the biology of aging and more clinical trials in elderly patients are needed to improve morbidity and mortality in elderly HF patients.